Knee Osteoarthritis Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography

Description

Knee Osteoarthritis Market is estimated to be valued at USD 9,228.4 Mn in 2026 and is expected to reach USD 19,842.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 11.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 9,228.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.60%	2033 Value Projection:	USD 19,842.3 Mn

Knee osteoarthritis (OA) is a progressive joint disease that slowly destroys the knee's cartilage causing pain, stiffness, swelling and limited movement. Knee osteoarthritis is one of the most common musculoskeletal diseases in the world and its prevalence is increasing due to ageing populations, obesity, sports injuries and sedentary lifestyles.

The knee osteoarthritis market is characterized by multiple segments such as medications for joint pain and inflammation, joint injections and visco supplements, orthotic aids, physiotherapies and a wide spectrum of surgical knee osteoarthritis treatment including knee replacement surgery. The market is witnessing growing interest in regenerative therapies, including platelet-rich plasma (PRP), stem cell therapies, and disease-modifying osteoarthritis drugs (DMOADs), supported by rising healthcare expenditure and continuous advancements in orthopedic care.

Market Dynamics

The global knee osteoarthritis market is driven by growing aging population, increasing prevalence of obesity, and growing incidence of joint injuries leading to a larger patient pool that needs long-term treatment. Growing awareness for early diagnosis, improving access to cutting-edge imaging technologies, and increasing investments in disease-modifying osteoarthritis drugs (DMOADs), biologics, and minimally invasive therapies are further contributing to the market growth.

However, a number of constraints are present in the market, such as high cost of advanced therapies and knee replacement procedures, limited reimbursement in developing countries, and lack of widely approved disease-modifying treatments. Nevertheless, expanding use of regenerative medicine modalities like stem cell and platelet-rich plasma (PRP) therapies, coupled with the implementation of AI-enabled diagnostics and digital health solutions will offer new opportunities for growth in knee osteoarthritis market.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global knee osteoarthritis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Sanofi, Bayer AG, GSK plc, Novartis AG, AbbVie Inc., Merck & Co., Inc., Johnson & Johnson, and Anika Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global knee osteoarthritis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global knee osteoarthritis market

Market Segmentation

Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
Hyaluronic acid
Non-steroidal anti-inflammatory drugs (NSAIDs)
Analgesics
Corticosteroid
Others
Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
Oral
Parenteral
Others
Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Pfizer Inc.
Eli Lilly and Company
Sanofi
Bayer AG
GSK plc
Novartis AG
AbbVie Inc.
Merck & Co., Inc.
Johnson & Johnson
Anika Therapeutics, Inc.

Product Code: CMI9913

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Knee Osteoarthritis Market, By Drug Type
- Global Knee Osteoarthritis Market, By Route of Administration
- Global Knee Osteoarthritis Market, By Distribution Channel
- Global Knee Osteoarthritis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Industry Trends

4. Global Knee Osteoarthritis Market, By Drug Type, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hyaluronic acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Non-steroidal anti-inflammatory drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Analgesics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Corticosteroid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Knee Osteoarthritis Market, By Route of Administration, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Knee Osteoarthritis Market, By Distribution Channel, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Knee Osteoarthritis Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Company Profile
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sanofi
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Bayer AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- GSK plc
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AbbVie Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Johnson & Johnson
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Anika Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. References and Research Methodology

References
Research Methodology
About us